NCT01444508 is a Phase 4 clinical trial of Ringer-lactate "SAD" in Bloodloss, sponsored by K. C. Rasmussen.

Who is sponsoring NCT01444508?

NCT01444508 is sponsored by K. C. Rasmussen.

What drugs are being tested in NCT01444508?

Interventions in NCT01444508: Ringer-lactate "SAD", HES 130/04.

Is NCT01444508 still recruiting?

NCT01444508 is currently status unknown. Last updated 12 December 2013.

Last reviewed 2013-12-12 · How we verify

NCT01444508

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

Status unknown Phase 4 Last updated 12 December 2013

What this trial tests

Phase 4 trial testing Ringer-lactate "SAD" in Bloodloss in 40 participants. Status unknown.

Timeline

1 September 2011

Primary endpoint
1 April 2013

1 December 2013

Quick facts

Lead sponsor	K. C. Rasmussen
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	40
Start date	1 September 2011
Primary completion	1 April 2013
Estimated completion	1 December 2013
Sites	1 location across Denmark

Drugs / interventions tested

Ringer-lactate "SAD" — full drug profile →
HES 130/04 — full drug profile →

Conditions studied

Bloodloss — all drugs for Bloodloss →

Sponsor

K. C. Rasmussen — full company profile →

Who can join

18 and older, any sex, with Bloodloss. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Effect of colloid versus crystalloid on laboratory coagulation.
Time frame: 5-7 hours
Coagulation is analysed in bloodsamples before, during (10 minutes post cystectomia), at the end of the operation and 2 hours later on. The bloodsamples are analysed by thromboelastography (5000 series TEG analyzer, Haemoscope Corporation, Niles IL, USA) besides the classic coagulation parametres: platelet count, INR, Fibrinogen, APTT, D-dimer and Haemoglobin, Amylase and Creatinin.

Sponsor's own description

In order to reduce bloodloss and need for transfusion to investigate the effect of colloid and crystalloid on coagulation assuming no difference between the groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01444508 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by K. C. Rasmussen
Last refreshed: 12 December 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01444508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing